Evotec OAI Extends Discovery Agreement with Solvay Pharmaceuticals
Evotec OAI AG announced a one-year extension of its Focused Library Agreement with Solvay Pharmaceuticals which was originally signed in January 2001.
Applying Evotec OAI's world class expertise in high-speed and computational chemistry, a dedicated team of Evotec OAI chemists will design and synthesise collections of small, drug-like molecules around selected Solvay templates. Solvay will use these high-quality compounds in screens against their targets to identify novel drug candidates. Evotec OAI has the potential to earn further clinical and market milestones.
Joern Aldag, President and Chief Executive Officer of Evotec OAI, commented: "This collaboration has set a standard on how we work collaboratively with our partners. Over the past two years we have demon-strated that our drug discovery expertise adds significant value to Solvay's programmes. We are delighted that Solvay decided to continue the partnership with Evotec OAI and to become one of our multi-year discovery partners."
Other news from the department science
